The Path To Commercialize CAR-T Cell Products – Science Trends
Science Trends |
The Path To Commercialize CAR–T Cell Products
Science Trends Among such treatments are genetically-engineered CAR T cells that bypass the natural function of patients’ T cells to efficiently target and kill tumors. Two CAR T cell products were recently approved by the FDA, and their administration is limited to … |
Epidermolysis Bullosa News |
Trial Shows Abeona’s Gene Therapy EB-101 Helps Wounds Heal in RDEB Patients
Epidermolysis Bullosa News Results from a Phase 1/2 trial in recessive dystrophic epidermolysis bullosa (RDEB) showed that gene therapy candidate EB-101 led to durable wound healing and improved quality of life, according to Abeona Therapeutics. The updated findings on Abeona’s … |
Seeking Alpha |
Gene Therapy AMT-061 Shows Clinical Benefit in Hemophilia B Patients in Recent Trial
Rare Disease Report New data presented by the gene therapy company uniQure at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting held in Chicago, Illinois, has shown that the company’s gene therapy product candidate, AMT-061, is clinically beneficial … UniQure’s AMT-060 shows treatment benefit in hemophilia B patients with pre-existing neutralizing antibodies; shares …Seeking Alpha uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 …PharmiWeb.com (press release) |